Diffuse large cell, B-cell type lymphoma with a novel translocation (2;22)(p23;q11.2)

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Malignant lymphomas, particularly diffuse large B-cell lymphoma, are characterized by specific genetic alterations.
• The anaplastic lymphoma kinase (ALK) gene, located at 2p23, is known to be involved in certain lymphomas, notably through the t(2;5) translocation.
• CD30 antigen expression is a common marker in anaplastic large cell lymphomas, but its absence in other large cell lymphomas warrants further investigation.

Observation:

• A patient presented with multiple subcutaneous nodules and bone marrow involvement.
• Cytogenetic analysis revealed a novel translocation, (2;22)(p23;q11.2), in the patient's bone marrow cells.
• Histological and immunohistochemical examination confirmed a malignant lymphoma, diffuse large cell type, with a CD30-negative B-cell immunophenotype.

Findings:

• This study reports the first instance of the (2;22)(p23;q11.2) translocation in a lymphoma case.
• The translocation potentially juxtaposes the anaplastic lymphoma kinase (ALK) gene at 2p23 with the immunoglobulin lambda light chain gene region at 22q11.2.
• The presence of this translocation in a CD30-negative, B-cell lineage lymphoma expands the known spectrum of ALK involvement in lymphoid malignancies.

Implications:

• This discovery suggests that ALK gene rearrangements may occur in a broader range of lymphomas than previously understood.
• The findings challenge the established association between ALK activation and CD30 expression in large cell lymphomas.
• Further research into this specific translocation could provide new diagnostic markers and therapeutic targets for specific lymphoma subtypes.